XLO

Xilio Therapeutics, Inc.

0.58 USD
+0.03 (+5.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Xilio Therapeutics, Inc. stock is down -7.62% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 February’s closed higher than January.

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.